A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Bibliographic Details
Main Authors: Hudis, Clifford, Swanton, Charles, Janjigian, Yelena Y, Lee, Ray, Sutherland, Stephanie, Lehman, Robert, Chandarlapaty, Sarat, Hamilton, Nicola, Gajria, Devika, Knowles, James, Shah, Jigna, Shannon, Keith, Tetteh, Ernestina, Sullivan, Daniel M, Moreno, Carolina, Yan, Li, Han, Hyo Sook
Format: Online
Language:English
Published: BioMed Central 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979046/
id pubmed-3979046
recordtype oai_dc
spelling pubmed-39790462014-04-08 A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors Hudis, Clifford Swanton, Charles Janjigian, Yelena Y Lee, Ray Sutherland, Stephanie Lehman, Robert Chandarlapaty, Sarat Hamilton, Nicola Gajria, Devika Knowles, James Shah, Jigna Shannon, Keith Tetteh, Ernestina Sullivan, Daniel M Moreno, Carolina Yan, Li Han, Hyo Sook Research Article BioMed Central 2013 2013-11-19 /pmc/articles/PMC3979046/ /pubmed/24252402 http://dx.doi.org/10.1186/bcr3577 Text en Copyright © 2013 Hudis et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Hudis, Clifford
Swanton, Charles
Janjigian, Yelena Y
Lee, Ray
Sutherland, Stephanie
Lehman, Robert
Chandarlapaty, Sarat
Hamilton, Nicola
Gajria, Devika
Knowles, James
Shah, Jigna
Shannon, Keith
Tetteh, Ernestina
Sullivan, Daniel M
Moreno, Carolina
Yan, Li
Han, Hyo Sook
spellingShingle Hudis, Clifford
Swanton, Charles
Janjigian, Yelena Y
Lee, Ray
Sutherland, Stephanie
Lehman, Robert
Chandarlapaty, Sarat
Hamilton, Nicola
Gajria, Devika
Knowles, James
Shah, Jigna
Shannon, Keith
Tetteh, Ernestina
Sullivan, Daniel M
Moreno, Carolina
Yan, Li
Han, Hyo Sook
A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
author_facet Hudis, Clifford
Swanton, Charles
Janjigian, Yelena Y
Lee, Ray
Sutherland, Stephanie
Lehman, Robert
Chandarlapaty, Sarat
Hamilton, Nicola
Gajria, Devika
Knowles, James
Shah, Jigna
Shannon, Keith
Tetteh, Ernestina
Sullivan, Daniel M
Moreno, Carolina
Yan, Li
Han, Hyo Sook
author_sort Hudis, Clifford
title A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
title_short A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
title_full A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
title_fullStr A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
title_full_unstemmed A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors
title_sort phase 1 study evaluating the combination of an allosteric akt inhibitor (mk-2206) and trastuzumab in patients with her2-positive solid tumors
description
publisher BioMed Central
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979046/
_version_ 1612075418389577728

Similar Items